Single Injection Adductor Canal Block vs Catheter for Total Knee Arthroplasty

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study investigates single injection adductor canal block (ACB) with or without intravenous dexamethasone and adductor canal catheter for pain management of total knee arthroplasty. This is a non-inferiority trial seeking to determine whether single injection ACB with dexamethasone is "no worse" than a continuous catheter.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of British Columbia
• Treatments: BB 1101; Bupivacaine; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Fentanyl; Ropivacaine

Criteria

Inclusion Criteria:

• Patients over or equal to the age of 18 years old who can understand the study protocol and are able to give consent

• Patients with an American Society of Anaesthesiology (ASA) classification 1 to 3

• Patients must have a preoperative oral 24 hour opioid consumption of less than or equal to 30 mg morphine equivalents

• Patients must be able to understand and be able to use patient controlled analgesia

• Patients must be undergoing a primary total knee arthroplasty with neuraxial anesthesia

Exclusion Criteria:

• Patients with a contraindication to neuraxial and/or regional anaesthesia

• Patients with an allergy to local anaesthetics

• Patients who have chronic pain not related to their knee joint

• Patients with chronic opioid use (daily or almost daily use >3 months)

• Patients with contraindications to dexamethasone (allergy, infection, Insulin dependent Diabetes Mellitus)

• Patients with pre-existing neuropathy

• Patients with hepatic failure

• Patients with renal failure with eGFR<60

• Patients with allergy to ketorolac or NSAIDs